Dimethylarginine dimethylaminohydrolase: A new therapeutic target for the modulation of nitric oxide and angiogenesis

J. P. Singh

Research output: Contribution to journalReview article

6 Scopus citations


Nitric oxide (NO) has a key role in promoting angiogenesis by increasing vasodilation, vascular permeability, endothelial cell proliferation and migration, and by modifying the activities of angiogenic mediators. NO is also critical for the mobilization of endothelial progenitor cells from the bone marrow which promotes vasculogenesis and angiogenesis. Studies have shown that the enzymes catalyzing NO synthesis are inhibited by the endogenously generated inhibitor asymmetric dimethylarginine (ADMA). Pharmacological agents targeted to modulate dimethyl-arginine dimethylaminohydrolase, the key enzyme metabolizing ADMA, may offer a potential strategy for developing novel pro- and anti-angiogenic therapies.

Original languageEnglish (US)
Pages (from-to)736-741
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Issue number9
StatePublished - Sep 1 2007



  • Angiogenesis
  • Asymmetric dimethylarginine
  • Dimethylarginine dimethylaminohydrolase
  • Nitric oxide
  • Progenitor cell

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this